GP 20091
Alternative Names: GP-20091Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator GEROPHARM
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase antizyme stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Diabetes mellitus
Most Recent Events
- 14 Sep 2022 GP 20091 is available for licensing as of 14 Sep 2022. https://geropharm.com/ (GEROPHARM pipeline, September 2022)
- 14 Sep 2022 Early research in Diabetes mellitus in Russia (Parenteral) before September 2022 (GEROPHARM pipeline, September 2022)